Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Letter - MedMira Reveal G2 Rapid HIV-1 Antibody Test

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

June 23, 2004

Mr. Hermes Chan
MedMira Labs
155 Chain Lake Drive, Bayers Lake
Halifax, Nova Scotia B3S 1B3

Re: BP000023/15
Product: MedMira Reveal G2 Rapid HIV-1 Antibody Test
Device Code: MZF

Date Received: 29-DEC-03

Dear Mr. Chan:

The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) has completed its review of your premarket approval supplement (PMA Supplement) for the Reveal TM G2 Rapid HIV-1 Antibody Test. This supplement is to allow for the addition of a procedural and reagent control line, a change in the packaging of the Colorimetric Detection Agent, and a change in the name of the device to Reveal TM G2 Rapid HIV-1 Antibody Test. We are pleased to inform you that the PMA supplement is approved subject to the conditions described below, as agreed upon in your letter dated June 14, 2004:

MedMira will submit to FDA within 6 months following the approval of this PMA supplement the results of a study comparing -------- determinations using ------------------------------------- for the testing process. This study will be done using 3 lots of conjugate.

If you have any questions concerning this approval order, please contact Hilary Cooper at (301) 827-5307.


--- signature ---

Hira L. Nakhasi, Ph.D.
Division of Emerging and Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Page Last Updated: 04/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.